Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis

The objective of this meta-analysis was to evaluate the prognostic utility of uric acid in hypertensive patients. We comprehensively searched PubMed and Embase databases (until July 31, 2020) to identify eligible studies that reported the association of uric acid with mortality and cardiovascular outcomes in hypertensive patients. Outcome measures included cardiovascular or all-cause mortality, coronary artery disease (CAD), stroke, and major adverse cardiovascular events (MACEs). Eleven eligible studies of 49,800 hypertensive patients were identified. For patients with the highest than those with reference lower group of uric acid level, the pooled hazard ratio (HR) was 1.51 (95% confidence interval [CI] 1.12 –2.02) for all-cause mortality, 1.68 (95% CI 1.28–2.20) for cardiovascular mortality, 1.31 (95% CI 1.10–1.55) for CAD, and 1.48 (95% CI 1.28–1.70) for MACEs. However, there was no significant association between elevated uric acid level and incident stroke in hypertensive patients. This meta -analysis indicates that elevated uric acid level is significantly associated with an increased risk of cardiovascular or all-cause mortality, CAD and MACEs in hypertensive patients. Hypertensive patients with highest uric acid level exhibited a tendency for reduced risk of stroke, but the differenc e is not significant.
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research